|9 Months Ended|
Sep. 30, 2020
|Risks and Uncertainties [Abstract]|
Note 11 – Concentrations
During the nine months ended September 30, 2020, we had two significant customers which accounted for 36% and 20% of sales.
We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.
At September 30, 2020, we had two customers which accounted for 100% of our account receivable balances.
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef